American Society of Hirudotherapy

Successful pediatric heart transplantation with bivalirudin use in a cyanotic single ventricle patient with an intracorporeal continuous flow ventricular assist device and heparin-induced thrombocytopenia

Case report published in Indian Journal of Thoracic and Cardiovascular Surgery (2025)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportClinical LiteratureDrug DevelopmentSainathan S, Mulinari L · Indian Journal of Thoracic and Cardiovascular Surgery, 2025

Abstract

We describe a case of profound coagulopathy during orthotopic heart transplantation in a cyanotic single ventricle pediatric patient with an intracorporeal continuous flow ventricular assist device performed on bivalirudin for heparin-induced thrombocytopenia. This was successfully managed with central veno-arterial extracorporeal membrane oxygenation and hemofiltration as an adjunct to treat bivalirudin-induced coagulopathy due to lack of a reversal agent for bivalirudin.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article

Summary

Successful orthotopic heart transplant in a cyanotic single ventricle pediatric patient on continuous-flow VAD with HIT, with bivalirudin anticoagulation managed using V-A ECMO and hemofiltration as adjuncts due to lack of bivalirudin reversal agent.

Why This Matters for Hirudotherapy

This case report describes a cyanotic single-ventricle pediatric patient with an intracorporeal continuous-flow ventricular assist device and heparin-induced thrombocytopenia who underwent orthotopic heart transplantation anticoagulated with bivalirudin. Profound coagulopathy developed and was managed with central veno-arterial extracorporeal membrane oxygenation and hemofiltration, partly because bivalirudin lacks a reversal agent. The abstract does not mention hirudin, leeches, leech therapy, or the leech secretome. The evidence is limited to a single case report with minimal detail on outcomes beyond acute management. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.

Citation

Reference (Vancouver style)

Sainathan S, Mulinari L. Successful pediatric heart transplantation with bivalirudin use in a cyanotic single ventricle patient with an intracorporeal continuous flow ventricular assist device and heparin-induced thrombocytopenia. Indian J Thorac Cardiovasc Surg. 2025;41(7):933-936. doi:10.1007/s12055-024-01892-6. PMID: 40535220

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.